80 results about "Phosphatidyl inositol" patented technology

The invention relates to an oral drug delivery system which delivers biologically active substances to the mucosal tissue of the intestine utilizing novel polymerized liposomes. Novel polymerizable fatty acids having a polymerizable group, a surfactant group, and a functional group, and optionally coupled to ligands which target mucosal tissue in the intestine are disclosed. Novel negatively charged polymerizable lipids which have phosphatidyl inositol (PI), phosphatidyl glycerol (PG) or phosphatidyl serine (PS) groups on a polymerizable backbone are also described.

In alternative embodiments, the invention provides phosphatidylinositol-specific phospholipase C (PI-PLC) enzymes, nucleic acids encoding them, antibodies that bind specifically to them, and methods for making and using them. Industrial methods and products comprising use of these phospholipases are also provided. In certain embodiments, provided herein are methods for hydration of non hydratable phospholipids (NHPs) within a lipid matrix. The methods enable migration of NHPs to an oil-water interface thereby allowing the NHPs to be reacted and / or removed from the lipids. In certain embodiments, provided is a method for removing NHPs, hydratable phospholipids, and lecithins from vegetable oils to produce a degummed oil or fat product that can be used for food production and / or non-food applications. In certain embodiments, provided herein are methods for hydration of NHPs followed by enzymatic treatment and removal of various phospholipids and lecithins. The methods provided herein can be practiced on either crude or water-degummed oils.

The present invention provides compositions and methods for use in enzyme replacement therapy. The inventors disclose a method of producing membrane bound enzymes in an active soluble form by eliminating the glycosylphosphatidylinositol (GPI) membrane anchor. In particular the inventors disclose a soluble active form of the membrane bound enzyme TNSALP which they produced by deleting the GPI anchor single peptide sequence. They have further shown that this composition is useful for treatment of hypophosphatasia. The inventors also disclose oligo acid amino acid variants thereof which specifically target bone tissue.

Disclosed herein are polar lipid mixtures, comprising glycerophospholipids such as phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS) and phosphatidyl-inositol (PI), and sphingolipids such as sphyngomyelin (SM). Most importantly, the ratio of phospholipids in said mixture is comparable to that of HMF, and is represented by SM>PC>PE>PS>PI or SM=PC>PE>PS>PI. Processes for the preparation of said mixtures and uses thereof are also described herein.

A lipid preparation including a glycerophospholipid or salt, conjugate and derivatives thereof, particularly phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidyl-inositol (PI), phosphatidylglycerol (PG) and phosphatidic acid (PA), and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and / or omega-6 acyl groups, wherein said PUFA is covalently bound to said glycerophospholipid. The preparation possesses an improved bioactivity, and is useful in the treatment of various cognitive and mental conditions and disorders and for maintenance of normal functions of brain-related systems and processes.

A lipid preparation including a glycerophospholipid or salt, conjugate and derivatives thereof, particularly phosphatidylserine (PS), phosphatidyicholine (PC), phosphatidylethanolamine (PE), phosphatidyl-inositol (PI), phosphatidylglycerol (PG) and phosphatidic acid (PA), and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and / or omega-6 acyl groups, wherein said PUFA is covalently bound to said glycerophospholipid. The preparation possesses an improved bioactivity, and is useful in the treatment of various cognitive and mental conditions and disorders and for maintenance of normal functions of brain-related systems and processes.

The present invention provides a pharmaceutical composition which is useful as a phosphatidylinositol 3 kinase (PI3K) inhibitor and an antitumor agent, and it provides a novel bicyclic or tricyclic fused heteroaryl derivative or a salt thereof which possesses an excellent PI3K inhibiting activity and cancer cell growth inhibiting activity.

In alternative embodiments, the invention provides phosphatidylinositol-specific phospholipase C (PI-PLC) enzymes, nucleic acids encoding them, antibodies that bind specifically to them, and methods for making and using them. Industrial methods and products comprising use of these phospholipases are also provided. In certain embodiments, provided herein are methods for hydration of non hydratable phospholipids (NHPs) within a lipid matrix. The methods enable migration of NHPs to an oil-water interface thereby allowing the NHPs to be reacted and / or removed from the lipids. In certain embodiments, provided is a method for removing NHPs, hydratable phospholipids, and lecithins from vegetable oils to produce a degummed oil or fat product that can be used for food production and / or non-food applications. In certain embodiments, provided herein are methods for hydration of NHPs followed by enzymatic treatment and removal of various phospholipids and lecithins. The methods provided herein can be practiced on either crude or water-degummed oils.

The invention discloses a method for enriching phosphatidyl inositol from antarctic krill. The method includes the steps: (1) adding 1 kilogram of frozen antarctic krill to 1-1.3 liters of ethanol solution with the volume fraction of 90-100%, stirring to extract for 4-6 times under natural conditions, keeping extraction each time for 1-3h, and filtering and combining extracting solutions so as to obtain filtrate; (2) concentrating the obtained filtrate under the pressure of negative 0.07-negative 0.09Mpa at the temperature of 60-65 DEG C until 8-10% of the volume of the filtrate remains so as to obtain concentrated extracting solution; (3) adding isometric normal hexane into the obtained concentrated extracting solution, uniformly mixing and statically layering so as to obtain transparent reddish bottom solution; and (4) removing the normal hexane from the obtained bottom solution by vaporizing under the pressure of negative 0.07-negative 0.09Mpa at the temperature of 50-55 DEG C so as to obtain oily solution, namely, a phosphatidyl-inositol-enriched product, wherein the product comprises 2.70-2.76% of phospholipid, and the phosphatidyl inositol accounts for 50.5-51.92% of the phospholipid. Re-extraction, separation, purification and the like can be further performed on the basis so as to obtain the phosphatidyl inositol.

The invention discloses a gastrodin multiphase liposome injection and a preparation method thereof. Gastrodin, soybean phosphatidylinositol, cholesterol, Twain 80, polyoxyethylene 40, hydrogenated castor oil, trehalose and EDTA-2Na which have specific weight ratios are prepared into the gastrodin multiphase liposome injection. The gastrodin multiphase liposome injection provided by the invention has excellent preparation stability and meets the demand of intravenous injection; after the gastrodin multiphase liposome injection is stored for a long time, the excellent encapsulation of the liposome is kept; the solubility of gastrodin is increased; the quality of preparation product is increased; the toxic side effect is reduced; the retention time of medicine in systemic circulation is increased; the bioavailability of the medicine is increased; the curative effect is obviously increased; and the preparation method is simple and is suitable for industrial production in bulk.

The invention discloses a method for detecting impurities in choline alfoscerate. The method comprises the following steps: with a mixed solution of 0.0005-0.002mol / L of ammonium formate solution and acetonitrile as a moving phase A and with a mixed solution of 0.03-0.05mol / L of ammonium formate solution and acetonitrile as a moving phase B, performing primary liquid chromatography detection on a choline alfoscerate test sample solution by a binary gradient elution process to obtain the contents of the impurities glycerol, choline chloride and glycerol phosphatidyl inositol; with acetonitrile and water as a moving phase, performing secondary liquid chromatography detection on the choline alfoscerate test sample to obtain the content of the impurity, namely glycerin phosphatidyl ethanolamine. According to the method provided by the invention, different chromatographic conditions can be set up for detecting different impurities so as to obtain the contents of all the known impurities, so that one-sidedness of judging the quality of the choline alfoscerate by only detecting some impurities and an aim of monitoring the quality of the choline alfoscerate comprehensively and effectively is achieved.

The invention discloses a traditional Chinese medicine preparation for treating cirrhosis and a preparation method thereof. The traditional Chinese medicine preparation is prepared from, by weight, 3-5 parts of hirudo, 1-3 parts of Rhizoma curcumae, 10-20 parts of Pu-er raw tea, 5-10 parts of Radix morindae officinalis, 0.2-0.8 part of pig lung extract, 5-20 parts of kelp, 5-15 parts of root of Litsea glutinosa and 10-25 parts of fried hedgehog hide, wherein active ingredients of pig lung extract are one or multiple of phosphatidylcholine, dipalmitoyl phosphatidylcholine, phosphatidyl ethanolamine, phosphatidylserine, phosphatidyl-inositol and sphingomyelin. The preparation method includes: subjecting raw materials to smashing, water extracting or supercritical CO2 extracting and mixing. A principle of regulating kidney, gallbladder and spleen at the same time is adopted, the traditional Chinese medicine preparation has efficacy of clearing heat for detoxification, soothing liver for choleresis, promoting diuresis to treat stranguria, calming liver to regulate qi, activating blood to remove stasis, strengthening heart to lower blood pressure, dispelling wind to stop pain and regulating immunity, is safe, reliable, free of toxic and side effect, short in treatment course, quick in action, low in cost, capable of treating both symptoms and root causes and worthy of wide popularization and application clinically.

The invention discloses an olmesartan ester liposome solid preparation and a preparation method thereof. Active ingredient-olmesartan ester, particularly-combined phosphatidyl inositol, di-stearoyl phosphatidyl glycerol, cholesterol succinate and tween 80 are prepared into liposome, the stability, the dissolution rate and the bioavailability of the preparation is greatly increased, the action is stable and lasting, and the curative effect is significant. The product quality of the preparation is increased, and the toxic and side effects are reduced.

Compounds having the structure which are selective inhibitors of P13K (phosphatidylinositol 3-kinase-delta), for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions.